We actively seek out relationships with organizations whose capabilities are synergistic with our own in further advancing molecular diagnostics in human health care.
BECKMAN COULTER
Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Their diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use their life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.
NICHOLAS CONOR INSTITUTE
The Nicholas Conor Institute is a non-profit medical research organization with the goals of identifying and developing both innovative therapies and original diagnostic approaches to treating childhood cancer. In order to achieve our goals we aim to develop efficient, mutually beneficial partnerships within both the academic and biomedical industry communities.
+ www.thenicholasconorinstitute.org
BIPAR SCIENCES
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. BiPar Sciences’ lead product candidate, iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. Iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.
COMPENDIA BIOSCIENCE
Ann Arbor-based Compendia Bioscience is dedicated to applying the global collection of cancer genomic data to impact patient treatment by enabling the discovery and development of better cancer diagnostics and treatments.
